Eiger Mountains

Investor Overview

Corporate Profile

Eiger is a clinical-stage biopharmaceutical company committed to developing and commercializing novel products for the treatment of rare diseases. Eiger has built a diverse, late-stage portfolio of well-characterized product candidates with the potential to address diseases for which the unmet medical need is high, a novel biology for treatment has been identified, and for which an effective therapy is urgently needed. The Eiger management team has extensive experience in the clinical development a...  More >>

Stock Quote

Recent News

More >>
Date Title and Summary
Toggle Summary Eiger to Present at Cantor 2019 Global Healthcare Conference
  PALO ALTO, Calif. , Sept. 27, 2019 /PRNewswire/ --   Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that Eiger management will present a corporate update at the Cantor
Toggle Summary Eiger BioPharmaceuticals to Participate in September Conferences
PALO ALTO, Calif. , Aug. 29, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that management will participate in the following upcoming investor
Toggle Summary Eiger Announces FDA Breakthrough Therapy Designation for Peginterferon Lambda for Treatment of Hepatitis Delta Virus Infection
-- Fourth Eiger Program Granted Breakthrough Therapy Designation PALO ALTO, Calif. , Aug. 20, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, today announced that the Food
Toggle Summary Eiger BioPharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Business Update
- First-Ever Phase 3 HDV International D-LIVR Study Enrolling - NDA and MAA filings for Progeria & Progeroid Laminopathies planned for Q4 2019 PALO ALTO, Calif. , Aug. 8, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted
Upcoming EventsMore >>
Date Title
Friday, November 08, 2019 through Tuesday, November 12, 2019
Location:
Boston

United States


Wednesday, November 20, 2019 through Thursday, November 21, 2019
Location:
NYC

United States


What's New
There are currently no items available.

Receive E-mail Alerts

Click here to sign up to receive e-mail alerts whenever Eiger BioPharmaceuticals posts new information to the site.